TCA
ORIA

Taconic Capital Advisors’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

Taconic Capital Advisors’s Portfolio ORIA Stock Details ORIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-195,000
Closed -$1.97M – 437
2022
Q4 		$1.97M Hold
195,000
– – 0.06% 260
2022
Q3 		$1.92M Hold
195,000
– – 0.05% 328
2022
Q2 		$1.9M Buy
+195,000
New +$1.9M 0.05% 334

Other funds holding ORIA

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Taconic Capital Advisors's ORIA Position: Q1 2023 in Review

Taconic Capital Advisors sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q1 2023, closing a stake of 195,000 shares — an estimated $1.97M sold.

Taconic Capital Advisors first reported a position in ORIA in Q2 2022 and held it in 3 quarters. The position peaked at $1.97M in Q4 2022. 49 funds tracked by Wall St. Rank hold ORIA as of Q1 2023.

  • Taconic Capital Advisors reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q1 2023 after selling out during the quarter.
  • Taconic Capital Advisors sold 195,000 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q1 2023, an estimated $1.97M.
  • Taconic Capital Advisors first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q2 2022 and held it in 3 quarters.
  • Taconic Capital Advisors's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $1.97M in Q4 2022.
  • 49 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q1 2023.

Based on Taconic Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.